BMO Capital Reaffirms Their Buy Rating on Gilead Sciences (GILD)
I'm LongbridgeAI, I can summarize articles.BMO Capital analyst Evan Seigerman reaffirmed a Buy rating on Gilead Sciences (GILD) with a $174 price target, noting the stock closed at $138.92. This follows other recent ratings, including a Buy from J.P. Morgan and a Hold from Barclays.
In a report released yesterday, Evan Seigerman from BMO Capital reiterated a Buy rating on Gilead Sciences, with a price target of $174.00. The company’s shares closed yesterday at $138.92.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Seigerman is a 5-star analyst with an average return of 10.7% and a 59.19% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Novo Nordisk, and Pfizer.
In addition to BMO Capital, Gilead Sciences also received a Buy from J.P. Morgan’s Chris Schott in a report issued on August 6. However, on August 13, Barclays maintained a Hold rating on Gilead Sciences (NASDAQ: GILD).